Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: Results of the
Ludy C H W Lutgens1, Peter C M Koper2, Jan J Jobsen3
1Maastricht Radiation Oncology (MAASTRO) Clinic, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Background:
Chemoradiation (RT-CT) is standard treatment for locally advanced cervical cancer (LACC). This study tried to establish if radiotherapy combined with hyperthermia (RT-HT) should be preferred in bulky and/or FIGO-stage ⩾III.
Methods:
In this open-label, multicenter randomized trial, patients with LACC were randomly assigned by a computer-generated, biased coin minimization technique to RT-CT or RT-HT. Central randomization was done with stratification by FIGO-stage, tumour diameter and nodal status. Primary endpoint was event free survival (EFS). Secondary endpoints were pelvic recurrence free survival (PRFS), overall survival (OS) and treatment related toxicity. Analysis was done by intention to treat.
Results:
The trial was closed prematurely (87 of 376 planned patients enrolled: 43 RT-CT; 44 RT-HT). Median follow-up time was 7.1 years. The cumulative incidence of an event was 33% in the RT-CT group and 35% in the RT-HT group. The corresponding hazard rate (HR) for EFS was 1.15 (CI: 0.56-2.36, p=0.7). Also the hazards for PRFS (0.94; CI 0.36-2.44) and OS (1.04; CI 0.48-2.23) at 5 years were comparable between both treatment arms as was grade ⩾3 radiation related late toxicity (6 RT-CT and 5 RT-HT patients).
Conclusion:
After 25% of intended accrual, data suggest comparable outcome for RT-CT and RT-HT.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
04:25Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases
Published on: November 8, 2024
Related Concept Videos
01:27Tumor Immunotherapy
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...